cisplatin,carboplatin,avelumab,domvanalimab,zimberelimab,sacituzumab govitecan,gemcitabine,pembrolizumab
merck,otsuka,gilead sciences,pfizer,gilead,arcus biosciences
['gu ', 'muc ,(-much)', 'avelumab', 'pembro', 'cisplatin', 'sacituzumab', 'urothelial', ' sg ', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'tropics-04', ' cis ', 'tps582', 'trophy,u-01', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'sacitu, govi', 'carboplatin', ' gem ', 'gemcitabine', 'zimberelimab', ' uc,(-ucsd),(-ucsf),', 'imab ']
primary analysis of trophy-u-01 cohort 2, a phase 2 study of sacituzumab govitecan (sg) in platinum (pt)-ineligible patients (pts) with metastatic urothelial cancer (muc) that progressed after prior checkpoint inhibitor (cpi) therapy. #gu23 
Medical Oncologist - Urologic Oncology. Hospital Universitario La Paz - IdiPAZ, Madrid